Arab & Middle East News
(ARABNEWSWIRE.COM, July 13, 2017 ) Hemophilia usually occurs in males it is estimated that about 1 in 5000 males born each year contains some form of hemophilia. Hemophilia is characterized into three levels depending upon on its severity as severe, moderate and mild. Around 80% of the patients suffering from hemophilia are considered to be severe. The worldwide incidence of hemophilia is estimated at more than 400,000 people.
View full report: http://www.marketdataforecast.com/market-reports/asia-pacific-hemophilia-management-market-313/
Asia-Pacific Hemophilia Management Market is driven by factors such as growing prevalence of the disease and increasing usage of recombinant product. Advancements in technology and rising investments into Research and developments are also fuelling the market growth.
However lack of awareness about the disease and limited access to the medication are the key factors hindering the market growth. Advancements in gene therapy which help in the treatment of hemophilia also provide immense growth opportunities. Asia-Pacific Hemophilia management market is segmented on the basis of type of hemophilia and type of drug.
Free sample of the report is available at: http://www.marketdataforecast.com/market-reports/asia-pacific-hemophilia-management-market-313/request-sample
By type of hemophilia it is further sub segmented into Hemophilia A and Hemophilia B. On the basis of drug type it is further sub segmented into Octocogalfa, Nonacogalfa, Desmopressin and other drugs. Hemophilia A is the largest segment accounting for approximately XX% due to elevated incidence of the condition.
Based on geography Asia-Pacific hemophilia management market is analyzed under various regions namely China, India, Japan, South Korea and Australia. Asia-Pacific region is estimated to be the fastest growing region owing to its high population base and increasing healthcare expenditure.
Buy now: https://www.marketdataforecast.com/cart/buy-now/asia-pacific-hemophilia-management-market-313
Within Asia-Pacific, Japan is a major market for hemophilia management due to high government support and wide spread awareness about the treatment options for hemophilia. India is estimated to grow at highest CAGR due to increasing incidence of the hemophilia. Some of the major companies discussed in the report are Biogen, Baxter International Inc., Pfizer Inc., Bayer Pharma AG, Novo Nordisk A/S, Grifols International SA, CSL Behring, Octapharma and Swedish Orphan Biovitrum AB
About Market Data Forecast:
The publisher of this report is Market Data Forecast whose forte lies in Market research and Business Intelligence. Handling both individual and corporate clients across multiple business domains they offer syndicated/customized research to suit the client’s research objective. Their research reports section offers a wide variety of market studies ranging from all-encompassing comprehensive market studies to product specific niche markets covering North America among other regions of the global market as well. For more info kindly visit, www.marketdataforecast.com
Sales Manager (International Business Development)
Market Data Forecast
Direct Line: +1-888-702-9626
Mobile: +91 998 555 0206
Visit MarketDataForecast Blog @ http://www.marketdataforecast.com/blog/
View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases
Market Data Forecast